KLS Martin adds Lithoz LithaBone TCP implants to its IPS Gate ordering platform
The German surgical device maker reports it is on course to reach 500 delivered ceramic implants by the end of Q3 2026
KLS Martin has listed patient-specific implants made from Lithoz’s LithaBone tricalcium phosphate (TCP) as a standard product on IPS Gate, its web-based platform for ordering Individual Patient Solutions.
The German company expects to reach 500 delivered ceramic implants by the end of Q3 2026. KLS Martin and Vienna-based Lithoz have collaborated for 12 years.
Surgeons can order the implants through the existing IPS workflow, according to Frank Reinauer, Senior Director Division Implant at KLS Martin.
“Individual-Patient-Specific ß-TCP status on IPS Gate means a broad availability; surgeons can plan, specify, and order a patient-specific bioceramic implant through the same digital workflow they already use for our other IPS solutions,” Reinauer said.
“That shortens the path from CT data to a case-specific, tailored-porosity scaffold in a surgeon’s hands, which translates directly into faster treatment planning and more predictable delivery timelines for patients that rely on bone-regenerating implants.”
KLS Martin prints the implants on Lithoz lithography-based ceramic manufacturing (LCM) printers. The companies stated that LCM allows patient-specific geometries and tailored porosities, which influence how quickly the scaffolds degrade and are replaced by newly formed bone.
Surgeons can fix the implants with titanium screws or KLS Martin’s SonicWeld Rx ultrasound-activated resorbable polymer pins.
“Launching LithaBone TCP implants as an official product on IPS Gate marks a true milestone for bioceramic 3D printing in surgery,” said Johannes Homa, Chief Executive Officer at Lithoz.
“What began 12 years ago as a research collaboration with KLS Martin has grown into a proven clinical pathway with scalable solutions. Seeing the success KLS Martin is having with our technology, as well as the general global adaptation of LCM in MedTech, shows that resorbable, additively manufactured bone-regenerating solutions are gaining broader clinical acceptance worldwide and demonstrate the growing role of additively manufactured bioceramic solutions in regenerative medicine.”
